Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 20(2011), 1 vom: Jan., Seite 99-106 |
| Beteiligte Personen: |
Ansell, Stephen M [VerfasserIn] |
|---|
| BKL: |
|---|
| Umfang: |
7 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC185570904X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC185570904X | ||
| 003 | DE-627 | ||
| 005 | 20230515133003.0 | ||
| 007 | tu | ||
| 008 | 110103s2011 xx ||||| 00| ||und c | ||
| 028 | 5 | 2 | |a sw101231_4 |
| 035 | |a (DE-627)OLC185570904X | ||
| 035 | |a (DE-599)GBVOLC185570904X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 082 | 0 | 4 | |a 610 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Ansell, Stephen M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells |
| 264 | 1 | |c 2011 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d London : Informa Healthcare, 1994 |g 20(2011), 1 vom: Jan., Seite 99-106 |w (DE-627)182171841 |w (DE-600)1182884-5 |w (DE-576)435516485 |x 1354-3784 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2011 |g number:1 |g month:01 |g pages:99-106 |g extent:7 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 20 |j 2011 |e 1 |c 1 |h 99-106 |g 7 | ||